{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:01:08Z","timestamp":1790262068304,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Xinjiang Uygur Autonomous Region","award":["Project No. 2023D01D15"],"award-info":[{"award-number":["Project No. 2023D01D15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02293-2","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T10:53:31Z","timestamp":1787482411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experimental evaluation of Nilotinib and Paclitaxel co-delivered via albumin nanoparticles as a therapeutic strategy for lung squamous cell carcinoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Xingfang","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"issue":"4","key":"2293_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10147-021-02108-2","volume":"27","author":"R Sharma","year":"2022","unstructured":"Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol. 2022;27(4):665\u201375.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"2293_CR2","doi-asserted-by":"publisher","first-page":"33299","DOI":"10.3402\/jchimp.v6.33299","volume":"6","author":"W Krimsky","year":"2016","unstructured":"Krimsky W, Muganlinskaya N, Sarkar S, Vulchi M, Patel P, Rao S, et al. The changing anatomic position of squamous cell carcinoma of the lung - a new conundrum. J Community Hosp Intern Med Perspect. 2016;6(6):33299.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2293_CR3","doi-asserted-by":"publisher","first-page":"945102","DOI":"10.3389\/fonc.2022.945102","volume":"12","author":"Q Guo","year":"2022","unstructured":"Guo Q, Liu L, Chen Z, Fan Y, Zhou Y, Yuan Z, et al. Current treatments for non-small cell lung cancer. Front Oncol. 2022;12:945102.","journal-title":"Front Oncol"},{"issue":"3","key":"2293_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-0042-1758552","volume":"71","author":"Y Wang","year":"2023","unstructured":"Wang Y, He C, Liu J, Wu S, Huang X, Zhang L, et al. The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma. Thorac Cardiovasc Surg. 2023;71(3):222\u201330.","journal-title":"Thorac Cardiovasc Surg"},{"key":"2293_CR5","doi-asserted-by":"publisher","first-page":"1467898","DOI":"10.3389\/fonc.2024.1467898","volume":"14","author":"Q Chen","year":"2024","unstructured":"Chen Q, Zheng X, Cheng W, Li J. Landscape of targeted therapies for lung squamous cell carcinoma. Front Oncol. 2024;14:1467898.","journal-title":"Front Oncol"},{"issue":"10","key":"2293_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41419-024-07155-x","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Liu P, Zhang R, Xing B, Chen G, Han L, et al. VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination. Cell Death Dis. 2024;15(10):772.","journal-title":"Cell Death Dis"},{"key":"2293_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers14194562","volume":"14","author":"A Ashrafi","year":"2022","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, et al. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers (Basel). 2022;14:19.","journal-title":"Cancers (Basel)"},{"key":"2293_CR8","doi-asserted-by":"crossref","unstructured":"Mohanty P, Pande B, Acharya R, Bhaskar L, Verma HK. Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways. Diseases. 2024;12(5).","DOI":"10.3390\/diseases12050093"},{"issue":"3","key":"2293_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41568-021-00427-0","volume":"22","author":"F Weiss","year":"2022","unstructured":"Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer. 2022;22(3):157\u201373.","journal-title":"Nat Rev Cancer"},{"key":"2293_CR10","doi-asserted-by":"publisher","first-page":"3658334","DOI":"10.1155\/2022\/3658334","volume":"2022","author":"J Liu","year":"2022","unstructured":"Liu J, Ma X, Cao L, Wei Y, Gao Y, Qu C, et al. Computational Drug Repurposing Approach to Identify Novel Inhibitors of ILK Protein for Treatment of Esophageal Squamous Cell Carcinoma. J Oncol. 2022;2022:3658334.","journal-title":"J Oncol"},{"issue":"4","key":"2293_CR11","first-page":"4114","volume":"18","author":"XL Ma","year":"2019","unstructured":"Ma XL, Yao H, Wang X, Wei Y, Cao LY, Zhang Q, et al. ILK predicts the efficacy of chemoradiotherapy and the prognosis of patients with esophageal squamous cell carcinoma. Oncol Lett. 2019;18(4):4114\u201325.","journal-title":"Oncol Lett"},{"issue":"5","key":"2293_CR12","doi-asserted-by":"publisher","first-page":"12532","DOI":"10.1080\/21655979.2022.2076497","volume":"13","author":"T Xu","year":"2022","unstructured":"Xu T, Ma XL, Wei Y, Cao LY, Gao Y, Liu J, et al. Integrin-linked kinase affects the sensitivity of esophageal squamous cell carcinoma cells to chemotherapy with cisplatin via the Wnt\/beta-catenin signaling pathway. Bioengineered. 2022;13(5):12532\u201347.","journal-title":"Bioengineered"},{"issue":"3","key":"2293_CR13","first-page":"e56545","volume":"16","author":"TC Prakash","year":"2024","unstructured":"Prakash TC, Enkemann S. Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia. Cureus. 2024;16(3):e56545.","journal-title":"Cureus"},{"issue":"18","key":"2293_CR14","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","volume":"121","author":"A Hochhaus","year":"2013","unstructured":"Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013;121(18):3703\u20138.","journal-title":"Blood"},{"issue":"9","key":"2293_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/fon-2018-0468","volume":"15","author":"T Sacha","year":"2019","unstructured":"Sacha T, Saglio G. Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol. 2019;15(9):953\u201365.","journal-title":"Future Oncol"},{"issue":"1","key":"2293_CR16","first-page":"vdaf150","volume":"7","author":"D Piccioni","year":"2025","unstructured":"Piccioni D, Juarez TM, Kesari SL, Rose L, Nomura N, Kesari S. Phase II trial of nilotinib in PDGFR-alpha-enriched recurrent high-grade gliomas. Neurooncol Adv. 2025;7(1):vdaf150.","journal-title":"Neurooncol Adv"},{"issue":"3","key":"2293_CR17","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.xcrm.2024.101435","volume":"5","author":"J Larkin","year":"2024","unstructured":"Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, et al. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. Cell Rep Med. 2024;5(3):101435.","journal-title":"Cell Rep Med"},{"issue":"12","key":"2293_CR18","doi-asserted-by":"publisher","first-page":"e0225887","DOI":"10.1371\/journal.pone.0225887","volume":"14","author":"RK Patel","year":"2019","unstructured":"Patel RK, Weir MC, Shen K, Snyder D, Cooper VS, Smithgall TE. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance. PLoS ONE. 2019;14(12):e0225887.","journal-title":"PLoS ONE"},{"issue":"2","key":"2293_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-010-1479-6","volume":"68","author":"KP Kim","year":"2011","unstructured":"Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, et al. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother Pharmacol. 2011;68(2):285\u201391.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2293_CR20","doi-asserted-by":"crossref","unstructured":"Jeitany M, Leroy C, Tosti P, Lafitte M, Le Guet J, Simon V et al. Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018;10(4).","DOI":"10.15252\/emmm.201707918"},{"issue":"05","key":"2293_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4149\/neo_2021_201126N1282","volume":"68","author":"S Wang","year":"2021","unstructured":"Wang S, Xie Y, Bao A, Li J, Ye T, Yang C, et al. Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer. Neoplasma. 2021;68(05):972\u201382.","journal-title":"Neoplasma"},{"issue":"3","key":"2293_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2174\/1871520621666210402110331","volume":"22","author":"L Meng","year":"2022","unstructured":"Meng L, Zhao P, Hu Z, Ma W, Niu Y, Su J, et al. Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer. Anticancer Agents Med Chem. 2022;22(3):596\u2013602.","journal-title":"Anticancer Agents Med Chem"},{"key":"2293_CR23","doi-asserted-by":"crossref","unstructured":"Gallanis AF, Perati SR, Canady SN, Epstein M, Moore N, Satterwhite AA et al. Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials. Ann Surg Oncol. 2026.","DOI":"10.1245\/s10434-026-19169-0"},{"key":"2293_CR24","doi-asserted-by":"crossref","unstructured":"Shin SJ, DeSouza A, Foster JC, Takebe N, O\u2019Sullivan Coyne G, Miller SB et al. Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1). J Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.3015"},{"key":"2293_CR25","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/DDDT.S169734","volume":"12","author":"Y Shen","year":"2018","unstructured":"Shen Y, Li W. HA\/HSA co-modified erlotinib\u2013albumin nanoparticles for lung cancer treatment. Drug Des Devel Ther. 2018;12:2285\u201392.","journal-title":"Drug Des Devel Ther"},{"key":"2293_CR26","doi-asserted-by":"crossref","unstructured":"Fu Y, Yang S, Liu Y, Liu J, Wang Q, Li F et al. Peptide Modified Albumin\u2013Paclitaxel Nanoparticles for Improving Chemotherapy and Preventing Metastasis. Macromol Biosci. 2022;22(3).","DOI":"10.1002\/mabi.202100404"},{"key":"2293_CR27","doi-asserted-by":"crossref","unstructured":"Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect. Polymers. 2022;14(13).","DOI":"10.3390\/polym14132601"},{"issue":"5","key":"2293_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s13346-018-0578-5","volume":"8","author":"KL Swetha","year":"2018","unstructured":"Swetha KL, Roy A. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. Drug Delivery Translational Res. 2018;8(5):1508\u201326.","journal-title":"Drug Delivery Translational Res"},{"issue":"3","key":"2293_CR29","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2293_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937\u201370.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"2293_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41574-020-00465-y","volume":"17","author":"ML Gild","year":"2021","unstructured":"Gild ML, Tsang VHM, Clifton-Bligh RJ, Robinson BG. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nat Rev Endocrinol. 2021;17(4):225\u201334.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2293_CR32","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1007\/s13346-024-01712-9","volume":"14","author":"M Dur\u00e1n-Lobato","year":"2024","unstructured":"Dur\u00e1n-Lobato M, Tovar S, de Oliveira Diz T, Chenlo M, \u00c1lvarez CV, Alonso MJ. Formulation of protein-loaded nanoparticles via freeze-drying. Drug Deliv Transl Res. 2024;14(12):3640\u201353.","journal-title":"Drug Deliv Transl Res"},{"key":"2293_CR33","doi-asserted-by":"publisher","first-page":"115239","DOI":"10.1016\/j.addr.2024.115239","volume":"207","author":"J Liu","year":"2024","unstructured":"Liu J, Cabral H, Mi P. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Deliv Rev. 2024;207:115239.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"2293_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/02652048.2023.2188943","volume":"40","author":"T Kovshova","year":"2023","unstructured":"Kovshova T, Mantrov S, Boiko S, Malinovskaya J, Merkulova M, Osipova N, et al. Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumour cells. J Microencapsul. 2023;40(4):246\u201362.","journal-title":"J Microencapsul"},{"key":"2293_CR35","doi-asserted-by":"publisher","first-page":"962652","DOI":"10.3389\/fphar.2022.962652","volume":"13","author":"A Alexandrova","year":"2022","unstructured":"Alexandrova A, Lomakina M. How does plasticity of migration help tumor cells to avoid treatment: Cytoskeletal regulators and potential markers. Front Pharmacol. 2022;13:962652.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2293_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4314\/tjpr.v19i1.8","volume":"19","author":"Q Wang","year":"2020","unstructured":"Wang Q, Yuan Y, Jiang M, Huang L, Huang J, Shen H. Imidazole-thiazolidinone inhibits oesophageal cancer cell proliferation via induction of apoptosis and cell cycle arrest at S phase. Trop J Pharm Res. 2020;19(1):51\u20136.","journal-title":"Trop J Pharm Res"},{"key":"2293_CR37","doi-asserted-by":"publisher","first-page":"1111991","DOI":"10.3389\/fphar.2023.1111991","volume":"14","author":"D Chen","year":"2023","unstructured":"Chen D, Liu X, Lu X, Tian J. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol. 2023;14:1111991.","journal-title":"Front Pharmacol"},{"key":"2293_CR38","doi-asserted-by":"publisher","first-page":"104673","DOI":"10.1016\/j.jddst.2023.104673","volume":"86","author":"S Nezhadi","year":"2023","unstructured":"Nezhadi S, Norouzi P, Rasouli A, Akbari Javar H, Ostad SN, Dorkoosh F. Co-delivery of paclitaxel and regorafenib by F127\/TPGS mixed micelles for triple negative breast cancer treatment. J Drug Deliv Sci Technol. 2023;86:104673.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"2293_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-019-0827-1","volume":"12","author":"L Lang","year":"2019","unstructured":"Lang L, Shay C, Zhao X, Xiong Y, Wang X, Teng Y. Simultaneously inactivating Src and AKT by saracatinib\/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma. J Hematol Oncol. 2019;12(1):132.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2293_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13048-023-01308-w","volume":"16","author":"M McFadden","year":"2023","unstructured":"McFadden M, Singh SK, Kinnel B, Varambally S, Singh R. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer. J Ovarian Res. 2023;16(1):220.","journal-title":"J Ovarian Res"},{"key":"2293_CR41","doi-asserted-by":"crossref","unstructured":"Roche J, Gemmill RM, Drabkin HA. Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer. Cancers (Basel). 2017;9(7).","DOI":"10.3390\/cancers9070072"},{"issue":"1","key":"2293_CR42","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1038\/s41598-020-60707-x","volume":"10","author":"AR Jung","year":"2020","unstructured":"Jung AR, Jung CH, Noh JK, Lee YC, Eun YG. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. Sci Rep. 2020;10(1):3652.","journal-title":"Sci Rep"},{"issue":"1","key":"2293_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s40001-025-02894-9","volume":"30","author":"C Wang","year":"2025","unstructured":"Wang C, Xiong M, Zhu Y, Li K, Ni J. EMP3 is upregulated upon epithelial-mesenchymal transition and contributes to EGFR-tyrosine kinase inhibitor resistance in lung adenocarcinoma. Eur J Med Res. 2025;30(1):642.","journal-title":"Eur J Med Res"},{"key":"2293_CR44","doi-asserted-by":"crossref","unstructured":"Islam W, Niidome T, Sawa T. Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors. J Pers Med. 2022;12(12).","DOI":"10.3390\/jpm12121964"},{"key":"2293_CR45","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.pdpdt.2022.102915","volume":"39","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther. 2022;39:102915.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"6","key":"2293_CR46","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s11426-020-9964-x","volume":"64","author":"Y Tu","year":"2021","unstructured":"Tu Y, Zheng R, Yu F, Xiao X, Jiang M, Yuan Y. Dual drug delivery system with flexible and controllable drug ratios for synergistic chemotherapy. Sci China Chem. 2021;64(6):1020\u201330.","journal-title":"Sci China Chem"},{"issue":"2","key":"2293_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13402-022-00760-y","volume":"46","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wu T, Wang Y, Chen Z, Chen J, Lu S, et al. Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis. Cell Oncol (Dordr). 2023;46(2):437\u201350.","journal-title":"Cell Oncol (Dordr)"},{"issue":"23","key":"2293_CR48","doi-asserted-by":"publisher","first-page":"e2409293","DOI":"10.1002\/advs.202409293","volume":"12","author":"F Xu","year":"2025","unstructured":"Xu F, Liu Y, Que Z, Luo B, Yang Y, Li Y, et al. Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies. Adv Sci (Weinh). 2025;12(23):e2409293.","journal-title":"Adv Sci (Weinh)"},{"key":"2293_CR49","doi-asserted-by":"publisher","first-page":"115259","DOI":"10.1016\/j.ejmech.2023.115259","volume":"252","author":"S Peng","year":"2023","unstructured":"Peng S, Yuan X, Li H, Wei Y, Zhou B, Ding G, et al. Recent progress in nanocarrier-based drug delivery systems for antitumour metastasis. Eur J Med Chem. 2023;252:115259.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"2293_CR50","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41417-024-00811-6","volume":"31","author":"A Khan","year":"2024","unstructured":"Khan A, Zhang Y, Ma N, Shi J, Hou Y. NF-\u03baB role on tumor proliferation, migration, invasion and immune escape. Cancer Gene Ther. 2024;31(11):1599\u2013610.","journal-title":"Cancer Gene Ther"},{"key":"2293_CR51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.lungcan.2019.07.006","volume":"135","author":"SL Ryan","year":"2019","unstructured":"Ryan SL, Beard S, Barr MP, Umezawa K, Heavey S, Godwin P, et al. Targeting NF-\u03baB-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer. 2019;135:217\u201327.","journal-title":"Lung Cancer"},{"issue":"6","key":"2293_CR52","first-page":"4819","volume":"17","author":"Q Li","year":"2019","unstructured":"Li Q, Chang Y, Mu L, Song Y. MicroRNA-9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF-\u03baB signaling pathway. Oncol Lett. 2019;17(6):4819\u201326.","journal-title":"Oncol Lett"},{"issue":"1","key":"2293_CR53","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41467-020-20664-5","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, et al. Dll1(+) quiescent tumor stem cells drive chemoresistance in breast cancer through NF-\u03baB survival pathway. Nat Commun. 2021;12(1):432.","journal-title":"Nat Commun"},{"key":"2293_CR54","doi-asserted-by":"publisher","first-page":"216709","DOI":"10.1016\/j.canlet.2024.216709","volume":"587","author":"T Chen","year":"2024","unstructured":"Chen T, Ruan Y, Ji L, Cai J, Tong M, Xue Y, et al. S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE\/NF-kB\/VEGF-D pathway. Cancer Lett. 2024;587:216709.","journal-title":"Cancer Lett"},{"issue":"1","key":"2293_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12967-023-04809-w","volume":"22","author":"M Ding","year":"2024","unstructured":"Ding M, Wang C, Hu J, She J, Shi R, Liu Y, et al. PLOD3 facilitated T cell activation in the colorectal tumor microenvironment and liver metastasis by the TNF-\u03b1\/ NF-\u03baB pathway. J Transl Med. 2024;22(1):30.","journal-title":"J Transl Med"},{"key":"2293_CR56","doi-asserted-by":"publisher","first-page":"115581","DOI":"10.1016\/j.bcp.2023.115581","volume":"212","author":"SL Huang","year":"2023","unstructured":"Huang SL, Chang TC, Sun NK. Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NF\u03baB activity. Biochem Pharmacol. 2023;212:115581.","journal-title":"Biochem Pharmacol"},{"key":"2293_CR57","doi-asserted-by":"crossref","unstructured":"Haider M, Elsherbeny A, Pittal\u00e0 V, Consoli V, Alghamdi MA, Hussain Z et al. Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer. Int J Mol Sci. 2022;23(3).","DOI":"10.3390\/ijms23031853"},{"issue":"2","key":"2293_CR58","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3109\/21691401.2014.968820","volume":"44","author":"V-M Le","year":"2014","unstructured":"Le V-M, Lang M-D, Shi W-B, Liu J-W. A collagen-based multicellular tumor spheroid model for evaluation of the efficiency of nanoparticle drug delivery. Artif Cells Nanomed Biotechnol. 2014;44(2):540\u20134.","journal-title":"Artif Cells Nanomed Biotechnol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02293-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02293-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02293-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:03:20Z","timestamp":1790258600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02293-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2293"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02293-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"340"}}